{"disease":{"id":"severe-alopecia-areata","name":"severe alopecia areata","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"deuruxolitinib","indication_name":"Severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqselvi","generic_name":"DEURUXOLITINIB","company_name":"Sun Pharm Inds Inc","drug_phase":"marketed","molecular_target":"JAK1, JAK2, TYK2","drug_class":"","quality_score":77,"revenue":"2600","mechanism":"Deuruxolitinib inhibits JAK1, JAK2, and TYK2, modulating cytokine and growth factor signaling involved in hematopoiesis and immune function."},{"drug_id":"deuruxolitinib","indication_name":"severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqselvi","generic_name":"DEURUXOLITINIB","company_name":"Sun Pharm Inds Inc","drug_phase":"marketed","molecular_target":"JAK1, JAK2, TYK2","drug_class":"","quality_score":77,"revenue":"2600","mechanism":"Deuruxolitinib inhibits JAK1, JAK2, and TYK2, modulating cytokine and growth factor signaling involved in hematopoiesis and immune function."},{"drug_id":"pf-06651600","indication_name":"Severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Litfulo","generic_name":"pf-06651600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ITK/TSK","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Litfulo works by blocking the ITK/TSK enzyme, which helps to stop the immune system from attacking hair follicles."},{"drug_id":"ritlecitinib-20-mg","indication_name":"Moderate to severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ritlecitinib 20 mg","generic_name":"ritlecitinib-20-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK3/STAT3 pathway","drug_class":"small molecule inhibitor","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe alopecia areata in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07152119","title":"A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07029711","title":"A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06562894","title":"Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"CSPC Ouyi Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07029828","title":"A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07200128","title":"A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Pfizer","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}